Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Helbig-Lang S, Petermann F. Tolerate or eliminate? A systematic review on the effects of safety behavior across anxiety disorders. Clin Psychol. 2010;17(3):218-233.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
3. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439.
4. National Alliance on Mental Illness. Anxiety Disorders. Available at https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/Anxiety-Disorders. Last accessed March 21, 2022.
5. National Institute of Mental Health. Anxiety Disorders. Available at https://www.nimh.nih.gov/health/topics/anxiety-disorders. Last accessed March 21, 2022.
6. Grassi M, Caldirola D, Di Chiaro NV, et al. Are respiratory abnormalities specific for panic disorder? A meta-analysis. Neuropsychobiology. 2014;70(1):52-60.
7. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184.
8. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.
9. Rosellini AJ, Lawrence AE, Meyer JF, Brown TA. The effects of extraverted temperament on agoraphobia in panic disorder.J Abnorm Psychol. 2010;119(2):420-426.
10. Copeland WE, Angold A, Shanahan L, Costello EJ. Longitudinal patterns of anxiety from childhood to adulthood: the Great Smoky Mountains Study. J Am Acad Child Adolesc Psychiatry. 2014;53(1):21-33.
11. Batelaan N, Spiker J, de Graaf R, Cujpers P. Mixed anxiety depression should not be included in DSM-5. J Nerv Ment Dis. 2012;200(6):495-498.
12. Hettema JM, Neale NC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158(10):1568-1578.
13. Fricchione G. Clinical practice: generalized anxiety disorder. N Engl J Med. 2004;351(7):675-682.
14. Zhang X, Norton J, Carrière I, Ritchie K, Chaudieu, Ancelin ML. Risk factors for late-onset generalized anxiety disorder: results from a 12-year prospective cohort (the ESPRIT study). Transl Psychiatry. 2015;5:e536.
15. Rodriguez BF, Weisberg RB, Pagano ME, et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis. 2006;194(2):91-97.
16. Rubio G and Lopez-Ibor JJ Jr. Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatr Scand. 2007;115(5):372-379.
17. Revicki DA. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012;140(2):103-112.
18. Marques L, Robinaugh DJ, LeBlanc NJ, Hinton D. Cross-cultural variations in the prevalence and presentation of anxiety disorders. Expert Rev Neurother. 2011;11(2):313-322.
19. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317-325.
20. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415-424.
21. Cosci F, Knuts IJ, Abrams K, Griez EJ, Schruers KR. Cigarette smoking and panic: a critical review of the literature. J Clin Psychiatry. 2010;71(5):606-615.
22. Leskin GA, Sheikh JI. Lifetime trauma history and panic disorder: findings from the National Comorbidity Survey. J Anxiety Disord. 2002;16(6):599-603.
23. Naragon-Gainey K. Meta-analysis of the relations of anxiety sensitivity to the depressive and anxiety disorders. Psychol Bull. 2010;136(1):128-150.
24. Bienvenu OJ, Stein MB, Samuels JF, et al. Personality disorder traits as predictors of subsequent first-onset panic disorder or agoraphobia. Compr Psychiatry. 2009;50(3):209-214.
25. Niccolai V, van Duinen MA, Griez EJ. Respiratory patterns in panic disorder reviewed: a focus on biological challenge tests. Acta Psychiatr Scand. 2009;120(3):167-177.
26. Zvolensky MJ, Feldner MT, Leen-Feldner EW, McLeish AC. Smoking and panic attacks, panic disorder, and agoraphobia: a review of the empirical literature. Clin Psychol Rev. 2005;25(6):761-789.
27. Farris SG, Robinson JD, Zvolensky MJ, et al. Panic attacks and smoking cessation among cancer patients receiving smoking cessation treatment. Addict Behav. 2016;61:32-39.
28. Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci. 2015;17(2):191-206.
29. Batelaan NM, de Graaf R, Penninx BW, van Balkom AJ, Vollebergh WA, Beekman AT. The 2-year prognosis of panic episodes in the general population. Psychol Med. 2010;40(1):147-157.
30. Batelaan NM, de Graaf R, Spijker J, et al. The course of panic attacks in individuals with panic disorder and subthreshold panic disorder: a population-based study. J Affect Disord. 2010;121(1-2):30-38.
31. Lieberman L, Gorka SM, Sarapas C, Shankman SA. Cognitive flexibility mediates the relation between intolerance of uncertainty and safety signal responding in those with panic disorder. Cogn Emot. 2016;30(8):1495-1503.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000.
33. Nocon A, Wittchen HU, Beesdo K, et al. Differential familial liability of panic disorder and agoraphobia. Depress Anxiety. 2008;25(5):422-434.
34. Imai H, Tajika A, Chen P, Pompoli A, Furukawa TA. Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. Cochrane Database Syst Rev. 2016;10:CD011170.
35. Wittchen HU, Nocon A, Beesdo K, et al. Agoraphobia and panic: prospective-longitudinal relations suggest a rethinking of diagnostic concepts. Psychother Psychosom. 2008;77(3):147-157.
36. Ritchie K, Norton J, Mann A, Carrière I, Ancelin ML. Late-onset agoraphobia: general population incidence and evidence for a clinical subtype. Am J Psychiatry. 2013;170(7):790-798.
37. Welzel FD, Luppa M, Pabst A, et al. Incidence of anxiety in latest life and risk factors. Results of the AgeCoDe/AgeQualiDe Study. Int J Environ Res Public Health. 2021;18(23):12786.
38. Hara N, Nishimura Y, Yokoyama C, et al. The development of agoraphobia is associated with the symptoms and location of a patient's first panic attack. Biopsychosoc Med. 2012;6(1):12.
39. Nay W, Brown R, Roberson-Nay R. Longitudinal course of panic disorder with and without agoraphobia using the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychiatry Res. 2013;208(1):54-61.
40. Ramsawh HJ, Weisberg RB, Dyck I, et al. Age of onset, clinical characteristics, and 15-year course of anxiety disorders in a prospective, longitudinal, observational study. J Affect Disord. 2011;132(1-2):260-264.
41. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
42. Brook CA, Schmidt LA. Social anxiety disorder: a review of environmental risk factors. Neuropsychiatr Dis Treat. 2008;4(1):123-143.
43. Stein MB, Gelernter J, Smoller JW. Genetic aspects of social anxiety and related traits. In: Bandelow B, Stein DJ (eds). Social Anxiety Disorder. New York, NY: Marcel Dekker; 2004: 197-214.
44. Hirshfeld-Becker DR, Biederman J, Henin A, et al. Behavioral inhibition in preschool children at risk is a specific predictor of middle childhood social anxiety: a five-year follow-up. J Dev Behav Pediatr. 2007;28(3):225-233.
45. Clauss JA, Blackford JU. Behavioral inhibition and risk for developing social anxiety disorder: a meta-analytic study. J Am Acad Child Adolesc Psychiatry. 2012;51(10):1066-1075.
46. Möller EL, Nikolić M, Majdandžić M, Bögels SM. Associations between maternal and paternal parenting behaviors, anxiety and its precursors in early childhood: a meta-analysis. Clin Psychol Rev. 2016;45:17-33.
47. Majdandžić M, de Vente W, Colonnesi C, Bögels SM. Fathers' challenging parenting behavior predicts less subsequent anxiety symptoms in early childhood. Behav Res Ther. 2018;109:18-28.
48. Fehm L, Pelissolo A, Furmark T, Wittchen HU. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol. 2005;15(4):453-462.
49. Plasencia ML, Alden LE, Taylor CT. Differential effects of safety behaviour subtypes in social anxiety disorder. Behav Res Ther. 2011;49(10):665-675.
50. Roth DA, Heimberg RG. Cognitive behavioral models of social anxiety disorder. Psychiatr Clin North Am. 2001;24(4):753-771.
51. Aune T, Stiles TC. Universal-based prevention of syndromal and subsyndromal social anxiety: a randomized controlled study.J Consult Clin Psychol. 2009;77(5):867-879.
52. Moreno-Peral P, Conejo-Cerón S, Rubio-Valera M, et al. Effectiveness of psychological and/or educational interventions in the prevention of anxiety: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2017;74(10):1021-1029.
53. La Greca AM, Ehrenreich-May J, Mufson L, Chan S. Preventing adolescent social anxiety and depression and reducing peer victimization: intervention development and open trial. Child Youth Care Forum. 2016;45(6):905-926.
54. Beard C, Moitra E, Weisberg RB, Keller MB. Characteristics and predictors of social phobia course in a longitudinal study of primary-care patients. Depress Anxiety. 2010;27(9):839-845.
55. Ramsawh HJ, Raffa SD, Edelen MO, Rende R, Keller MB. Anxiety in middle adulthood: effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorder. Psychol Med. 2009;39(4):615-624.
56. Stinson FS, Dawson DA, Chou SP, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2007;37(7):1047-1059.
57. Davey GC, McDonald AS, Hirisave U, et al. A cross-cultural study of animal fears. Behav Res Ther. 1998;36(7-8):735-750.
58. Olatunji BO, Sawchuk CN. Disgust: characteristic features, social manifestations, and clinical implications. J Soc Clin Psychol. 2005;24(7):932-962.
59. Czajkowski N, Kendler KS, Tambs K, Røysamb E, Reichborn-Kjennerud T. The structure of genetic and environmental risk factors for phobias in women. Psychol Med. 2011;41(9):1987-1995.
60. Van Houtem CM, Laine ML, Boomsma DI, Ligthart L, van Wijk AJ, De Jongh A. A review and meta-analysis of the heritability of specific phobia subtypes and corresponding fears. J Anxiety Disord. 2013;27(4):379-388.
61. Manicavasagar V, Marnane C, Pini S, et al. Adult separation anxiety disorder: a disorder comes of age. Curr Psychiatry Rep. 2010;12(4):290-297.
62. Shear K, Jin R, Ruscio AM, Walters EE, Kessler RC. Prevalence and correlates of estimated DSM-IV child and adult separation anxiety disorder in the national comorbidity survey replication. Am J Psychiatry. 2006;163(6):1074-1083.
63. Gesi C, Abelli M, Cardini A, et al. Separation anxiety disorder from the perspective of DSM-5: clinical investigation among subjects with panic disorder and associations with mood disorders spectrum. CNS Spectr. 2016;21(1):70-75.
64. Rochester J, Baldwin DS. Adult separation anxiety disorder: accepted but little understood. Hum Psychopharmacol. 2015;30(1):1-3.
65. Kossowsky J, Pfaltz MC, Schneider S, Taeymans J, Locher C, Gaab J. The separation anxiety hypothesis of panic disorder revisited: a meta-analysis. Am J Psychiatry. 2013;170(7):768-781.
66. Farb DH, Ratner MH. Targeting the modulation of neural circuitry for the treatment of anxiety disorders. Pharmacol Rev. 2014;66(4):1002-1032.
67. Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am. 2009;32(3):549-575.
68. Roy AK. Extreme Anxiety Reflects Aberrant Functional Connectivity in Prefrontal-Amygdalar Networks. Available at https://2015anxietyanddepressionconferen.sched.org/event/2u2N/extreme-anxiety-reflects-aberrant-functional-connectivity-in-prefrontal-amygdalar-networks. Last accessed March 21, 2022.
69. Johnson PL, Federici LM, Shekhar A. Etiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacks. Neurosci Biobehav Rev. 2014;46(Pt 3):429-454.
70. Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorders. PT. 2013;38(1):30-44.
71. Strawn JR, Wehry AM, Chu WJ, et al. Neuroanatomic abnormalities in adolescents with generalized anxiety disorder: a voxel-based morphometry study. Depress Anxiety. 2013;30(9):842-848.
72. Tromp DP, Grupe DW, Oathes DJ, et al. Reduced structural connectivity of a major frontolimbic pathway in generalized anxiety disorder. Arch Gen Psychiatry. 2012;69(9):925-934.
73. Diefenbach GJ, Goethe JW. Does TMS Hold Promise for Generalized Anxiety Disorder? Available at https://www.psychiatrictimes.com/special-reports/does-tms-hold-promise-generalized-anxiety-disorder. Last accessed March 21, 2022.
74. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157(4):493-505.
75. Roy-Byrne PP, Cowley DS. Search for pathophysiology of panic disorder. Lancet. 1998;352(9141):1646-1647.
76. Dresler T, Guhn A, Tupak SV, et al. Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder.J Neural Transm (Vienna). 2013;120(1):3-29.
77. Abelson JL, Khan S, Liberzon I, Young EA. HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety. 2007;24(1):66-76.
78. Benke C, Alius MG, Hamm AO, Pane-Farre CA. Cue and context conditioning to respiratory threat: effects of suffocation fear and implications for the etiology of panic disorder. Int J Psychophysiol. 2018;124:33-42.
79. Kircher T, Arolt V, Jansen A, et al. Effect of cognitive-behavioral therapy on neural correlates of fear conditioning in panic disorder. Biol Psychiatry. 2013;73(1):93-101.
80. Kunas SL, Yang Y, Straube B, et al. The impact of depressive comorbidity on neural plasticity following cognitive behavioral therapy in panic disorder with agoraphobia. J Affect Disord. 2019;245:451-460.
81. Reinecke A, Thilo K, Filippini N, Croft A, Harmer CJ. Predicting rapid response to cognitive-behavioural treatment for panic disorder: the role of hippocampus, insula, and dorsolateral prefrontal cortex. Behav Res Ther. 2014;62:120-128.
82. Wittmann A, Schlagenhauf F, Guhn A, et al. Anticipating agoraphobic situations: the neural correlates of panic disorder with agoraphobia. Psychol Med. 2014;44(11):2385-2396.
83. Lueken U, Straube B, Reinhardt I, et al. Altered top-down and bottom-up processing of fear conditioning in panic disorder with agoraphobia. Psychol Med. 2014;44(2):381-394.
84. Lueken U, Straube B, Wittchen HU, et al. Therapygenetics: anterior cingulate cortex-amygdala coupling is associated with 5-HTTLPR and treatment response in panic disorder with agoraphobia. J Neural Transm (Vienna). 2015;122(1):135-144.
85. Knuts I, Esquivel G, Kenis G, et al. Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia. Eur Neuropsychopharmacol. 2014;24(8):1222-1228.
86. Perna G, Daccò S, Menotti R, Caldirola D. Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. Neuropsychiatr Dis Treat. 2011;7:621-637.
87. Brühl AB. Structural brain changes due to cognitive-behavioural group therapy in social anxiety disorder: conference abstract.J Psychopharmacol. 2015;29:A118.
88. Robinson OJ, Krimsky M, Lieberman L, Allen P, Vytal K, Grillon C. The dorsal medial prefrontal (anterior cingulate) cortex–amygdala aversive amplification circuit in unmedicated generalised and social anxiety disorders: an observational study. Lancet Psychiatry. 2014;1(4):294-302.
89. Freitas-Ferrari MC, Hallak JE, Trzesniak C, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature.Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(4):565-580.
90. Schwartz CE, Wright CI, Shin LM, Kagan J, Rauch SL. Inhibited and uninhibited infants "grown up:" adult amygdalar response to novelty. Science. 2003;300(5627):1952-1953.
91. Faravelli C, Lo Sauro C, Godini L, et al. Childhood stressful events, HPA axis and anxiety disorders. World J Psychiatry. 2012;2(1):13-25.
92. Dieleman GC, Huizink AC, Tulen JH, et al. Alterations in HPA-axis and autonomic nervous system functioning in childhood anxiety disorders point to a chronic stress hypothesis. Psychoneuroendocrinology. 2015;51:135-150.
93. Straube T, Mentzel HJ, Miltner WH. Neural mechanisms of automatic and direct processing of phobogenic stimuli in specific phobia. Biol Psychiatry. 2006;59(2):162-170.
94. Straube T, Mentzel HJ, Miltner WH. Waiting for spiders: brain activation during anticipatory anxiety in spider phobics. Neuroimage. 2007;37(4):1427-1436.
95. Schweckendiek J, Klucken T, Merz CJ, et al. Weaving the (neuronal) web: fear learning in spider phobia. Neuroimage. 2011;54(1):681-688.
96. Page AC. The role of disgust in faintness elicited by blood and injection stimuli. J Anxiety Disord. 2003;17(1):45-58.
97. Ipser JC, Singh L, Stein DJ. Meta-analysis of functional brain imaging in specific phobia. Psychiatry Clin Neurosci. 2013;67(5):311-322.
98. Milrod B, Markowitz JC, Gerber AJ, et al. Childhood separation anxiety and the pathogenesis and treatment of adult anxiety. Am J Psychiatry. 2014;171(1):34-43.
99. Atli O, Bayin M, Alkin T. Hypersensitivity to 35% carbon dioxide in patients with adult separation anxiety disorder. J Affect Disord. 2012;141(2-3):315-323.
100. Battaglia M, Ogliari A, D'Amato F, Kinkead R. Early-life risk factors for panic and separation anxiety disorder: insights and outstanding questions arising from human and animal studies of CO2 sensitivity. Neurosci Biobehav Rev. 2014;46(Pt 3):455-464.
101. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
102. Psychiatry Online. Highlights of Changes from DSM-IV-TR to DSM-5. Available at https://dsm.psychiatryonline.org/doi/10.1176/appi.books.9780890425596.changes. Last accessed March 21, 2022.
103. National Institute of Mental Health. Research Domain Criteria (RDoC). Available at https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc. Last accessed March 21, 2022.
104. Moran M. Updated DSM-5 Text Revisions to Be Released in March. Available at https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2022.1.20. Last accessed March 21, 2022.
105. Pies RW. Why Panic Attacks Are Nearly Always Pathological. Available at https://www.psychiatrictimes.com/panic-disorder/why-panic-attacks-are-nearly-always-pathological. Last accessed March 21, 2022.
106. Craske MG, Tsao JC. Assessment and treatment of nocturnal panic attacks. Sleep Med Rev. 2005;9(3):173-184.
107. Katerndahl DA. Chest pain and its importance in patients with panic disorder: an updated literature review. Prim Care Companion J Clin Psychiatry. 2008;10(5):376-383.
108. Pfaltz MC, Michael T, Meyer AH, Wilhelm FH. Reexperiencing symptoms, dissociation, and avoidance behaviors in daily life of patients with PTSD and patients with panic disorder with agoraphobia. J Trauma Stress. 2013;26(4):443-450.
109. Hagenaars MA, van Minnen A, Hoogduin KA. Reliving and disorganization in posttraumatic stress disorder and panic disorder memories. J Nerv Ment Dis. 2009;197(8):627-630.
110. Pfaltz MC, Michael T, Meyer AH, Wilhelm FH. Reexperiencing symptoms, dissociation, and avoidance behaviors in daily life of patients with PTSD and patients with panic disorder with agoraphobia. J Trauma Stress. 2013;26(4):443-450.
111. Comer JS, Blanco C, Hasin DS, et al. Health-related quality of life across the anxiety disorders. J Clin Psychiatry. 2011;72(1):43-50.
112. Sherbourne CD, Sullivan G, Craske MG, et al. Functioning and disability levels in primary care out-patients with one or more anxiety disorders. Psychol Med. 2010;40(12):2059-2068.
113. Swinson RP, Cox BJ, Woszczyna CB. Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. CMAJ. 1992;147(6):878-883.
114. Marcks BA, Weisberg RB, Keller MB. Psychiatric treatment received by primary care patients with panic disorder with and without agoraphobia. Psychiatr Serv. 2009;60(6):823-830.
115. Bienvenu OJ, Hettema JM, Neale MC, Prescott CA, Kendler KS. Low extraversion and high neuroticism as indices of genetic and environmental risk for social phobia, agoraphobia, and animal phobia. Am J Psychiatry. 2007;164(11):1714-1721.
116. Bruno A, Muscatello MRA, Pandolfo G, et al. Does personality matter? Temperament and character dimensions in panic subtypes. Noro Psikiyatr Ars. 2018;55(4):325-329.
117. Moscovitch DA, Waechter S, Bielak T, Rowa K, McCabe RE. Out of the shadows and into the spotlight: social blunders fuel fear of self-exposure in social anxiety disorder. J Anxiety Disord. 2015;34:24-32.
118. Starcevic V. Separation anxiety disorder in adults: is the neglect real? Aust N Z J Psychiatry. 2013;47(2):188-189.
119. Pini S, Abelli M, Troisi A, et al. The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. J Anxiety Disord. 2014;28(8):741-746.
120. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.
121. Locke AB, Kirst N, Shultz CG. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;91(9):617-624.
122. King M, Nazareth I, Levy G, et al. Prevalence of common mental disorders in general practice attendees across Europe. Br J Psychiatry. 2008;192(5):362-367.
123. Calleo J, Stanley MA, Greisinger A, et al. Generalized anxiety disorder in older medical patients: diagnostic recognition, mental health management and service utilization. J Clin Psychol Med Settings. 2009;16(2):178-185.
124. Robbins JM, Kirmayer LJ, Cathébras P, Yaffe MJ, Dworkind M. Physician characteristics and the recognition of depression and anxiety in primary care. Med Care. 1994;32(8):795-812.
125. Mathias S, Fifer S, Mazonson P, Lubeck DP, Buesching DP, Patrick DL. Necessary but not sufficient: the effect of screening and feedback on outcomes of primary care patients with untreated anxiety. J Gen Intern Med. 1994;9(11):606-615.
126. Haynes R, Devereaux P, Guyatt G. Physicians' and patients' choices in evidence based practice. BMJ. 2002;324(7350):1350.
127. Kasper S. Anxiety disorders: under-diagnosed and insufficiently treated. Int J Psychiatry Clin Pract. 2006;10(Suppl 1):3-9.
128. Roy-Byrne P, Russo J, Dugdale DC, Lessler D, Cowley D, Katon W. Undertreatment of panic disorder in primary care: role of patient and physician characteristics. J Am Board Fam Pract. 2002;15(6):443-450.
130. Taylor CT, Laposa JM, Alden LE. Is avoidant personality disorder more than just social avoidance? J Pers Disord. 2004;18(6):571-594.
131. Cox BJ, Pagura J, Stein MB, Sareen J. The relationship between generalized social phobia and avoidant personality disorder in a national mental health survey. Depress Anxiety. 2009;26(4):354-362.
132. Grant BF, Hasin DS, Stinson FS, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(3):363-374.
133. Primary Care Collaborative. Patient Health Questionnaire—Mental Health Tools. Available at https://www.pcpcc.org/resource/patient-health-questionnaire-mental-health-tools. Last accessed March 21, 2022.
134. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA. 1999;282(18):1737-1744.
135. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.
136. Farach FJ, Pruitta LD, Jun JJ, Jerud AB, Zoellner LA, Roy-Byrne PP. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord. 2012;26(8):833-843.
137. Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther. 2015;149:150-190.
138. Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci. 2011;13(4):423-437.
139. Buckner JD, Cromer KR, Merrill KA, et al. Pretreatment intervention increases treatment outcomes for patients with anxiety disorders. Cognit Ther Res. 2009;33(1):126-137.
140. Bögels SM, Knappe S, Clark LA. Adult separation anxiety disorder in DSM-5. Clin Psychol Rev. 2013;33(5):663-674.
141. Morone NE, Belnap HB, He F, Mazumdar S, Weiner DK, Rollman BL. Pain adversely affects outcomes to a collaborative care intervention for anxiety in primary care. J Gen Intern Med. 2012;28(1):58-66.
142. Gerrits M, van Oppen P, Leone SS van Marwijk HW, van der Horst HE, Penninx BW. Pain, not chronic disease, is associated with the recurrence of depressive and anxiety disorders. BMC Psychiatry. 2014;14:187.
143. Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, Yonkers KA. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38(3):365-374.
144. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525.
145. National Institute for Health and Clinical Excellence. Generalised Anxiety Disorder and Panic Disorder in Adults: Management. Available at https://www.nice.org.uk/guidance/cg113/chapter/1-Guidance. Last accessed March 21, 2022.
146. Naragon-Gainey K, Gallagher MW, Brown TA. A longitudinal examination of psychosocial impairment across the anxiety disorders. Psychol Med. 2014;44(8):1691-1700.
147. Harmer CJ, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178-1184.
148. Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol Med. 2012;42(12):2609-2617.
149. Harmer CJ. Psychological mechanisms of antidepressant drug action: conference abstract. J Psychopharmacol. 2015;29:A123.
150. Reinecke A, Waldenmaier L, Cooper MJ, Harmer CJ. Changes in automatic threat processing precede and predict clinical changes with exposure-based cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2013;73(11):1064-1070.
151. Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. Cochrane Database Syst Rev. 2016;4:CD011004.
152. Rector NA, Man V, Lerman B. The expanding cognitive-behavioural therapy treatment umbrella for the anxiety disorders: disorder-specific and transdiagnostic approaches. Can J Psychiatry. 2014;59(6):301-309.
153. Batelaan NM, Van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. Int J Neuropsychopharmacol. 2012;15(3):403-415.
154. Kahl KG, Winter L, Schweiger U. The third wave of cognitive behavioural therapies: what is new and what is effective? Curr Opin Psychiatry. 2012;25(6):522-528.
155. Kim YW, Lee SH, Choi TK, et al. Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety. 2009;26(7):601-606.
156. Lee SH, Ahn SC, Lee YJ, Choi TK, Yook KH, Suh SY. Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder. J Psychosom Res. 2007;62(2):189-195.
157. Kim MK, Lee KS, Kim B, Choi TK, Lee SH. Impact of mindfulness-based cognitive therapy on intolerance of uncertainty in patients with panic disorder. Psychiatry Investig. 2016;13(2):196-202.
158. Ainsworth B. How Does Mindfulness Target Anxiety? The Effect of Focused Attention and Open-Monitoring Meditation on Negative Thought Intrusions. Presented at: British Association for Psychopharmacology 2015 Conference; Bristol, UK; July 26–29, 2015.
159. Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. Behav Ther. 2004;35(4):639-665.
160. Arch JJ, Eifert GH, Davies C, Plumb Vilardaga JC, Rose RD, Craske MG. Randomized clinical trial of cognitive behavioral therapy (CBT) versus acceptance and commitment therapy (ACT) for mixed anxiety disorders. J Consult Clin Psychol. 2012;80(5):750-765.
161. Haller H, Breilmann P, Schröter M, Dobos G, Cramer H. A systematic review and meta-analysis of acceptance- and mindfulness-based interventions for DSM-5 anxiety disorders. Sci Rep. 2021;11(1):20385.
162. Meuret AE, Wolitzky-Taylor KB, Twohig MP, Craske MG. Coping skills and exposure therapy in panic disorder and agoraphobia: latest advances and future directions. Behav Ther. 2012;43(2):271-284.
163. Milrod B, Busch F, Singer MB, Aronson AC. Manual of Panic-Focused Psychodynamic Psychotherapy – Extended Range. New York, NY: Taylor and Francis Group; 2012.
164. Hofmann SG, Mundy EA, Curtiss J. Neuroenhancement of exposure therapy in anxiety disorders. AIMS Neurosci. 2015;2(3):123-138.
165. Hofmann SG, Smits JA, Rosenfield D, et al. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013;170(7):751-758.
166. Demertzis KH, Craske MG. Cognitive-Behavioral Therapy for Anxiety Disorders in Primary Care. Available at http://primarypsychiatry.com/cognitive-behavioral-therapy-for-anxiety-disorders-in-primary-care. Last accessed March 21, 2022.
167. Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B. Maximizing exposure therapy: an inhibitory learning approach.Behav Res Ther. 2014;58:10-23.
168. Buchholz JL, Abramowitz JS. The therapeutic alliance in exposure therapy for anxiety-related disorders: a critical review. J Anxiety Disord. 2020;70:102194.
169. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry. 1962;119:432-438.
170. Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013;28(1):7-20.
171. Spiegel DA. Efficacy studies of alprazolam in panic disorder. Psychopharmacol Bull. 1998;34(2):191-195.
172. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder. 2nd ed. Washington, DC: American Psychiatric Publishing; 2009.
173. Davies SJC. Drug Treatments for Anxiety Disorders. Presented at: 29th Annual Geriatric Medicine Refresher Day; London, Ontario, Canada; May 6, 2015.
174. Mavissakalian MR. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry. 2003;15(3-4):171-180.
175. Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr. 2005;27(1):18-24.
176. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226-247.
178. Lexicomp Online. Available at https://online.lexi.com/lco/action/login. Last accessed March 21, 2022.
179. Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:212290.
180. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013;14(5):578-585.
181. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
182. Gommoll C, Forero G, Mathews M, et al. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. Int Clin Psychopharmacol. 2015;30(6):297-306.
183. Gommoll C, Durgam S, Mathews M, et al. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety. 2015;32(6):451-459.
184. Sansone RA, Sansone LA. Emergency Psychiatry Update. Available at https://www.reliasmedia.com/articles/134475-emergency-psychiatry-update. Last accessed March 21, 2022.
185. Reinhold JA. Pharmacological Strategies for Generalized Anxiety Disorder. Available at https://www.psychiatrictimes.com/special-reports/pharmacological-strategies-generalized-anxiety-disorder. Last accessed March 21, 2022.
186. Pae CU, Wang SM, Han C, et al. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res. 2015;64:88-98.
187. Jacobsen PL, Mahableshwarkar AR, Palo WA, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr. 2016;21(5):367-378.
188. Celikyurt IK, Mutlu O, Ulak G. Serotonin noradrenaline reuptake inhibitors (SNRIs). In: Lu R-B (ed). Effects of Antidepressants. Rijeka: InTech; 2012.
189. Auclair AL, Martel JC, Assié MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338-347.
190. Matsumoto M, Tachibana K, Togashi H, et al. Chronic treatment with milnacipran reverses the impairment of synaptic plasticity induced by conditioned fear stress. Psychopharmacology (Berl). 2005;179(3):606-612.
191. Tachibana K, Matsumoto M, Togashi H, et al. Milnacipran, a serotonin and noradrenaline reuptake inhibitor, suppresses long-term potentiation in the rat hippocampal CA1 field via 5-HT1A receptors and alpha 1-adrenoceptors. Neurosci Lett. 2004;357(2):91-94.
192. Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers. Clin Drug Investig. 2011;31(3):155-167.
193. Maity N, Ghosal MK, Gupta A, Sil A, Chakraborty S, Chatterjee S. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol. 2014;46(4):433-437.
194. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62(11):1217-1227.
195. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004;55(3):320-322.
196. Nakagawa A, Watanabe N, Omori IM, et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009:3:CD006529.
197. Durgam S, Chen C, Migliore R, Prakash C, Thase ME. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Depress Anxiety. 2019;36(3):225-2234.
198. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166.
199. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 1994;114(4):559-565.
200. Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother. 2011;12(10):1623-1632.
202. Demyttenaere K. Agomelatine in treating generalized anxiety disorder. Expert Opin Investig Drugs. 2014;23(6):857-864.
203. De Berardis D, Fornaro M, Serroni N, et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. Int J Mol Sci. 2015;16(1):1111-1130.
204. Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry. 2015;3(1):4.
205. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28(9):835-854.
206. Nutt D, Mandel F, Baldinetti F. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model. J Psychopharmacol. 2009;23(8):867-873.
207. Wright C, Downing J, Mungall D, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol. 2013;4:192.
208. Kinrys G, Worthington JJ, Wygant L, Nery F, Reese H, Pollack MH. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry. 2007;68(7):1010-1013.
209. Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study.J Clin Psychiatry. 2006;67(10):1573-1576.
210. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder.J Clin Psychiatry. 2004;65(9):1219-1222.
211. Knapp CM, Ciraulo DA, Sarid-Segal O, et al. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015;35(1):34-42.
212. Kreys TJ, Phan SV. A literature review of quetiapine for generalized anxiety disorder. Pharmacotherapy. 2015;35(2):175-188.
213. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;12:CD008120.
215. DrugLib.com. Hydroxyzine (Hydroxyzine Hydrochloride). Available at http://www.druglib.com/druginfo/hydroxyzine. Last accessed March 21, 2022.
216. Snowman AM, Snyder SH. Cetirizine: actions on neurotransmitter receptors. J Allergy Clin Immunol. 1990;86(6 Pt 2):1025-1028.
217. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010;12:CD006815.
218. Llorca P, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002;63(11):1020-1027.
219. Lader M, Scotto J. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998;139(4):402-406.
220. Grohol JM. Top 25 Psychiatric Medication Prescriptions for 2018. Available at https://psychcentral.com/blog/top-25-psychiatric-medications-for-2018. Last accessed March 21, 2022.
221. Johnson B, Streltzer J. Risks associated with long-term benzodiazepine use. Am Fam Physician. 2013;88(4):224-226.
222. Royal Australian College of General Practitioners. Prescribing Drugs of Dependence in General Practice, Part B: Benzodiazepines. Available at https://www.racgp.org.au/getattachment/1beeb924-cf7b-4de4-911e-f7dda3e3f6e9/Part-B.aspx. Last accessed March 21, 2022.
223. Royal Australian and New Zealand College of Psychiatrists. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry. 2003;37(6):641-656.
224. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-192.
225. Westra HA, Stewart SH, Conrad BE. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. J Anxiety Disord. 2002;16(3):233-246.
226. Watanabe N, Churchill R, Furukawa T. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry. 2007;7:18.
227. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001;58(7):681-686.
229. Hood SD, Norman A, Hince DA, et al. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol. 2014;77(2):285-294.
230. Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014;171(1):44-53.
231. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 2005;10(1):49-56.
232. Pfizer Pharmaceuticals. Xanax (Alprazolam). Available at https://www.pfizer.com/products/product-detail/xanax. Last accessed March 21, 2022.
233. Ashton H. Risks of dependence on benzodiazepine drugs: a major problem of long term treatment. BMJ. 1989;298(6666):103-104.
234. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66(Suppl 2):9-13.
235. Movig KL, Mathjssen MP, Nagel PH, et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev. 2004;36(4):631-636.
236. Finkle WD, Der JS, Greenland S, et al. Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J Am Geriatr Soc. 2011;59(10):1883-1890.
237. Liebrenz M, Gehring M-T, Buadze A, Caflisch C. High-dose benzodiazepine dependence: a qualitative study of patients' perception on cessation and withdrawal. BMC Psychiatry. 2015;15:116.
238. Lugoboni F, Quaglio G. Exploring the dark side of the moon: the treatment of benzodiazepine tolerance. Br J Clin Pharmacol. 2014;77(2):239-241.
239. Hulse G, O'Neill G, Morris N, et al. Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series. J Psychopharmacol. 2013;27(2):222-227.
240. Quaglio GL, Pattaro C, Gerra G, et al. High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilised with clonazepam. Psychiatry Res. 2012;198(3):457-462.
241. Saxon L, Borg S, Hiltunen AJ. Reduction of aggression during benzodiazepine withdrawal: effects of flumazenil. Pharmacol Biochem Behav. 2010;96(2):148-151.
242. Huh J, Goebert D, Takeshita J, Lu BY, Kang M. Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord. 2011;13(2):PCC.08r00709.
243. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafig R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883-892.
244. Kjernisted K, McIntosh D. Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag. 2007;3(1):59-69.
245. Tedeschini E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than four weeks' duration. J Clin Psychiatry. 2011;72(1):98-118.
246. Institute for Clinical Systems Improvement. Guidelines: Depression, Adult in Primary Care. Available at https://www.icsi.org/guideline/depression. Last accessed March 21, 2022.
247. Pittman CM. Targeting Areas of the Brain for Change: Techniques for Assessing Sources of Anxiety in the Brain. Available athttps://2015anxietyanddepressionconferen.sched.org/event/2tai/targeting-areas-of-the-brain-for-change-techniques-for-assessing-sources-of-anxiety-in-the-brain. Last accessed March 21, 2022.
248. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72-81.
249. Fava GA, Bernardi M, 1, Tomba E, Rafanelli C. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2007;10(6):835-838.
250. Cortes JA, Radhakrishnan R. A case of amelioration of venlafaxine-discontinuation "brain shivers" with atomoxetine. Prim Care Companion CNS Disord. 2013;15(2).
251. Petit J, Sansone RA. A case of interdose discontinuation symptoms with venlafaxine extended release. Prim Care Companion CNS Disord. 2013;15(2).
252. Nelson JC, Spyker DA. Morbidity and mortality associated with medications used in the treatment of depression: an analysis of cases reported to U.S. poison control centers, 2000–2014. Am J Psychiatry. 2017;174:5.
253. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992;49(4):282-288.
254. Kessler KC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998;155(5):613-619.
255. Farris SG, Zvolensky MJ, Blalock JA, Schmidt NB. Negative affect and smoking motives sequentially mediate the effect of panic attacks on tobacco-relevant processes. Am J Drug Alcohol Abuse. 2014;40(3):230-239.
256. Robinson J, Sareen J, Cox BJ, Bolton JM. Role of self-medication in the development of comorbid anxiety and substance use disorders: a longitudinal investigation. Arch Gen Psychiatry. 2011;68(8):800-807.
257. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol. 2005;1:91-111.
258. Covin R, Ouimet AJ, Seeds PM, Dozois DJ. A meta-analysis of CBT for pathological worry among clients with GAD. J Anxiety Disord. 2008;22(1):108-116.
259. Hanrahan F, Field AP, Jones FW, Davey GC. A meta-analysis of cognitive therapy for worry in generalized anxiety disorder. Clin Psychol Rev. 2013;33(1):120-132.
260. Thorp SR, Ayers CR, Nuevo R, Stoddard JA, Sorrell JT, Wetherell JL. Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry. 2009;17(2):105-115.
261. Anxiety and Depression Association of America. Clinical Practice Review for GAD. Available at https://adaa.org/resources-professionals/practice-guidelines-gad. Last accessed March 21, 2022.
262. Robinson E, Titov N, Andrews G, McIntyre K, Schwencke G, Solley K. Internet treatment for generalized anxiety disorder: a randomized controlled trial comparing clinician vs. technician assistance. PLoS One. 2010;5(6):e10942.
263. Knekt P, Lindfors O, Laaksonen MA, et al. Quasi-experimental study on the effectiveness of psychoanalysis, long-term and short-term psychotherapy on psychiatric symptoms, work ability and functional capacity during a 5-year follow-up. J Affect Disord. 2011;132(1-2):37-47.
264. Herring MP, O'Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients: a systematic review. Arch Intern Med. 2010;170(4):321-331.
265. Hoge EA, Bui E, Marques L, et al. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013;74(8):786-792.
267. Roszkowska J, Geraci SA. Management of insomnia in the geriatric patient. Am J Med. 2010;123(12):1087-1090.
268. Roy-Byrne P, Veitengruber JP, Bystritsky A, et al. Brief intervention for anxiety in primary care patients. J Am Board Fam Med. 2009;22(2):175-186.
269. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022-1030.
270. Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010;13(2):229-241.
271. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep. 2005;28(2):187-193.
272. Wang SM, Woo YS, Kim NK, Na HR, Lim HK, Bahk WM. Agomelatine for the treatment of generalized anxiety disorder: a meta-analysis. Clin Psychopharmacol Neurosci. 2020;18(3):423-433.
273. Kreys TJM, Phan SV. A literature review of quetiapine for generalized anxiety disorder. Pharmacotherapy. 2015;35(2):175-188.
274. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50(11):884-895.
275. Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol. 2014;29(1):64-72.
276. Jacobsen PL, Clayton AH, Mahableshwarkar AR, Palo W, Chen, Y, Dragheim M. The Effect of Vortioxetine on Sexual Dysfunction During the Treatment of Adults with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD). Presented at: ASCP Annual Meeting; June 16–19, 2014. Available at http://ascpmeeting.org/wp-content/uploads/2014/05/ASCP-Poster-Abstract-Book-Online.pdf. Last accessed March 21, 2022.
277. Mancini M, Perna G, Rossi A, Petralia A. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. Expert Opin Pharmacother. 2010;11(7):1167-1181.
278. Youssef NA, Rich CL. Does acute treatment with sedatives/hypnotics for anxiety in depressed patients affect suicide risk? A literature review. Ann Clin Psychiatry. 2008;20(3):157-169.
279. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF 3rd. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. Focus. 2014;12(3):347-358.
280. Beck JG, Stanley MA, Baldwin LE, Deagle EA 3rd, Averill PM. Comparison of cognitive therapy and relaxation training for panic disorder. J Consult Clin Psychol. 1994;62(4):818-826.
281. Meuret AE, Rosenfield D, Seidel A, Bhaskara L, Hofmann SG. Respiratory and cognitive mediators of treatment change in panic disorder: evidence for intervention specificity. J Consult Clin Psychol. 2010;78(5):691-704.
282. Salkovskis PM, Clark DM, Hackmann A. Treatment of panic attacks using cognitive therapy without exposure or breathing retraining. Behav Res Ther. 1991;29(2):161-166.
283. Van den Hout M, Arntz A, Hoekstra R. Exposure reduced agoraphobia but not panic, and cognitive therapy reduced panic but not agoraphobia. Behav Res Ther. 1994;32(4):447-451.
284. Manoharan A, McMartin K, Young C, Gajic-Veljanoski O, Ali A, Walter M. Internet-delivered cognitive behavioural therapy for major depression and anxiety disorders: a health technology assessment. Ont Health Technol Assess Ser. 2019;19(6):1-199.
285. Olthuis JV, Watt MC, Bailey K, Hayden JA, Stewart SH. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2016;3:CD011565.
286. Pompoli A, Furukawa TA, Efthimiou O, Imai H, Tajika A, Salanti G. Dismantling cognitive-behaviour therapy for panic disorder: a systematic review and component network meta-analysis. Psychol Med. 2018;48(12):1945-1953.
288. Ural C, Belli H, Tabo A, Akbudak M. Open-longitudinal study of the effect of dissociative symptoms on the response of patients with panic disorder to venlafaxine. Compr Psychiatry. 2015;57:112-116.
289. Moylan S, Staples J, Ward SA, Rogerson J, Stein DJ, Berk M. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 2011;31(5):647-652.
290. Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A review of alprazolam use, misuse, and withdrawal. J Addict Med. 2018;12(1): 4-10.
291. Hoffart A, Hedley LM, Svanøe K, Langkaas TF, Sexton H. Agoraphobia with and without panic disorder: a 20-year follow-up of integrated exposure and psychodynamic therapy. J Nerv Ment Dis. 2016;204(2):100-107.
292. Gloster AT, Klotsche J, Gerlach AL, et al. Timing matters: change depends on the stage of treatment in cognitive behavioral therapy for panic disorder with agoraphobia. J Consult Clin Psychol. 2014;82(1):141-153.
293. Gloster AT, Sonntag R, Hoyer J, et al. Treating treatment-resistant patients with panic disorder and agoraphobia using psychotherapy: a randomized controlled switching trial. Psychother Psychosom. 2015;84(2):100-109.
294. Hoffart A, Hedley LM, Svanøe K, Sexton H. Cognitive and guided mastery therapies for panic disorder with agoraphobia: 18-year long-term outcome and predictors of long-term change. Clin Psychol Psychother. 2016;23(1):1-13.
295. Pitti CT, Peñate W, de la Fuente J, et al. The combined use of virtual reality exposure in the treatment of agoraphobia. Actas Esp Psiquiatr. 2015;43(4):133-141.
296. Van Apeldoorn FJ, Van Hout WJ, Timmerman ME, Mersch PP, den Boer JA. Rate of improvement during and across three treatments for panic disorder with or without agoraphobia: cognitive behavioral therapy, selective serotonin reuptake inhibitor or both combined. J Affect Disord. 2013;150(2):313-319.
297. Payne LA, White KS, Gallagher MW, et al. Second-stage treatments for relative nonresponders to cognitive behavioral therapy (CBT) for panic disorder with or without agoraphobia-continued CBT versus SSRI: a randomized controlled trial. Depress Anxiety. 2016;33(5):392-399.
298. Perna G, Alpini D, Caldirola D, Raponi G, Cesarani A, Bellodi L. Serotonergic modulation of the balance system in panic disorder: an open study. Depress Anxiety. 2003;17(2):101-106.
299. Perna G, Caldirola D. Is panic disorder a disorder of physical fitness? A heuristic proposal. F1000Res. 2018;7:294.
300. Marks IM, Swinson RP, Basoglu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry. 1993;162:776-782.
301. Helbig-Lang S, Richter J, Lang T, et al. The role of safety behaviors in exposure-based treatment for panic disorder and agoraphobia: associations to symptom severity, treatment course, and outcome. J Anxiety Disord. 2014;28(8):836-844.
302. Hoffart A, Øktedalen T, Svanøe K, Hedley LM, Sexton H. Predictors of short- and long-term avoidance in completers of inpatient group interventions for agoraphobia. J Affect Disord. 2015;181:33-40.
303. Porter E, Chambless DL. A systematic review of predictors and moderators of improvement in cognitive-behavioral therapy for panic disorder and agoraphobia. Clin Psychol Rev. 2015;42:179-192.
304. Tillfors M, Furmark T, Carlbring P, Andersson G. Risk profiles for poor treatment response to internet-delivered CBT in people with social anxiety disorder. J Anxiety Disord. 2015;33:103-109.
305. Davis ML, Smits JA, Hofmann SG. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Expert Opin Pharmacother. 2014;15(16):2281-2291.
306. Pollack MH, Jensen JE, Simon NM, Kaufman RI, Renshaw PF. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):739-743.
307. Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008;28(6):1021-1037.
308. Wilhelm FH, Roth WT. Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther. 1997;35(9): 831-841.
309. Soeter M, Kindt M. An abrupt transformation of phobic behavior after a post-retrieval amnesic agent. Biol Psychiatry. 2015;78(12):880-886.
310. Hofmann SG. D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety. 2014;31(3):175-177.
311. Burkner PC, Bittner N, Holling H, Buhlman U. D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: a meta-analysis. PLoS One. 2017;12(3):e0173660.
312. Mataix-Coils D, Fernandez de la Cruz L, Monzani B, et al. D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry. 2017;74(5):501-510.
313. Ori R, Amos T, Bergman H, Soares-Weiser K, Ipser JC, Stein DJ. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. Cochrane Database Syst Rev. 2015;5:CD007803.
314. Soravia LM, Heinrichs M, Winzeler L, et al. Glucocorticoids enhance in vivo exposure-based therapy of spider phobia. Depress Anxiety. 2014;31(5):429-435.
315. Steudte-Schmiedgen S, Fay E, Capitao L, Kirschbaum C, Reinecke A. Hydrocortisone as an adjunct to brief cognitive-behavioural therapy for specific fear: endocrine and cognitive biomarkers as predictors of symptom improvement. J Psychopharmacol. 2021;35(6):641-651.
316. Telch MJ, Bruchey AK, Rosenfield D, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry. 2014;171(10):1091-1098.
317. Friedman RA. A Drug to Cure Fear. Available at https://www.nytimes.com/2016/01/24/opinion/sunday/a-drug-to-cure-fear.html. Last accessed March 21, 2022.
318. Meuret AE, Wilhelm FH, Ritz T, Roth WT. Feedback of end-tidal pCO2 as a therapeutic approach for panic disorder. J Psychiatr Res. 2008;42(7):560-568.
319. Meuret AE, Rosenfield D, Hofmann SG, Suvak MK, Roth WT. Changes in respiration mediate changes in fear of bodily sensations in panic disorder. J Psychiatric Res. 2009;4(6)3:634-641.
320. Schlaepfer TE, George MS, Mayberg H. WFSBP guidelines on brain stimulation treatments in psychiatry. World J Biol Psychiatry. 2010;11(1):2-18.
321. Li H, Wang J, Li C, Xiao Z. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults. Cochrane Database Syst Rev. 2014;9:CD009083.
322. Paes F, Machado S, Arias-Carrión O, et al. The value of repetitive transcranial magnetic stimulation (rTMS) for the treatment of anxiety disorders: an integrative review. CNS Neurol Disord Drug Targets. 2011;10(5):610-620.
323. Mantovani A, Aly M, Dagan Y, Allart A, Lisanby SH. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. J Affect Disord. 2013;144(1-2):153-159.
324. Kang JI Lee H, Jhung K, et al. Frontostriatal connectivity changes in major depressive disorder after repetitive transcranial magnetic stimulation: a randomized sham-controlled study. J Clin Psychiatry. 2016;77(9):e1137-e1143.
325. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825-836.
326. Das RK, Kamboj SK, Ramadas M, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl). 2013;226(4):781-792.
327. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121-130.
328. Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Pharmacological properties of cannbidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018;27(4):327-335.
330. do Rego JL, Vaudry D, Vaudry H. The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis. PLoS One. 2015;10(3):e0120473.
331. Samalin L, Charpeaud T, Llorca PM. Asenapine in bipolar I disorder: evidence and place in patient management. Ther Adv Chronic Dis. 2013;4(1):5-14.
332. Huang X, Li C, Li WH, et al. Clinical evaluation of the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder: a randomized open-label trial. Hum Psychopharmacol. 2013;28(6):594-599.
333. Vadnal R, Parthasarathy L, Parthasarathy R. Role of inositol in the treatment of psychiatric disorders. CNS Drugs. 1997;7(1):6-16.
334. Einat H, Clenet F, Shaldubina A, Belmaker RH, Bourin M. The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. Behav Brain Res. 2001;118(1):77-83.
335. Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997;7(2):147-155.
336. Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001;21(3):335-339.
337. Saeed SA, Bloch RM, Antonacci DJ. Herbal and dietary supplements for treatment of anxiety disorders. Am Fam Physician. 2007;76(4):549-556.
338. Zheng H, Zhang L, Li L, et al. High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1189-1195.
339. Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol. 2014;29(1):55-63.
340. De Sousa A. Herbal medicines and anxiety disorders: an overview. J Med Plants Stud. 2013;1(6):18-23.
341. Sarris J, Byre GJ, Bousman CA, et al. Kava for generalized anxiety disorder: a 16-week double-blind, randomised, placebo-controlled study. Aust N Z J Psychiatry. 2020;54(3):288-297.
342. Ooi SL, Henderson P, Pak SC. Kava for generalized anxiety disorder: a review of current evidence. J Altern Complement Med. 2018;24(8):770-780.
343. Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the lavender oil preparation silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17(2):94-99.
344. Kasper S, Gastpar M, Muller WE, et al. Lavender oil preparation silexan is effective in generalized anxiety disorder: a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859-869.
345. Strickland JC, Smith MA. The anxiolytic effects of resistance exercise. Front Psychol. 2014;5:753.
346. Vorkapic CF, Rangé B. Reducing the symptomatology of panic disorder: the effects of a yoga program alone and in combination with cognitive-behavioral therapy. Front Psychiatry. 2014;5:177.
347. Katzman MA, Vermani M, Gerbarg PL, et al. A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities. Int J Yoga. 2012;5(1):57-65.
348. Khalsa MK, Greiner-Ferris JM, Hofmann SG, Khalsa SB. Yoga-enhanced cognitive behavioral therapy (Y-CBT) for anxiety management: a pilot study. Clin Psychol Psychother. 2015;22(4):364-371.
349. U.S. Preventive Services Task Force. Draft Recommendation Statement: Screening for Anxiety in Children and Adolescents. Available at https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/screening-anxiety-children-adolescents. Last accessed April 15, 2022.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.